The Aflac (NYSE: AFL) duck is one of the strongest brands today. It’s genius marketing. But there’s much more to this behemoth than a clever and enduring ad campaign. The stock is a must-own. I first wrote about Aflac for StreetAuthority three years ago. The stock is higher than when I first profiled it, and the earnings projections are right about where I put them (give or take a few cents). Yet the market is still not that crazy about the stock. Good — that means better prices for us. #-ad_banner-#With a market cap of close to $30… Read More
The Aflac (NYSE: AFL) duck is one of the strongest brands today. It’s genius marketing. But there’s much more to this behemoth than a clever and enduring ad campaign. The stock is a must-own. I first wrote about Aflac for StreetAuthority three years ago. The stock is higher than when I first profiled it, and the earnings projections are right about where I put them (give or take a few cents). Yet the market is still not that crazy about the stock. Good — that means better prices for us. #-ad_banner-#With a market cap of close to $30 billion, Aflac sells supplemental health and life insurance in the U.S. and Japan. Most products are underwritten on an individual basis, but the company began writing group policies in recent years. In the U.S., Aflac’s product focus is primarily asset and income loss due to illness or injury. In Japan, the company’s focus is on designing products designed to help pay medical costs not covered under Japan’s national health insurance system. This is where I see the most opportunity for growth in the U.S. business. But more on that later. Aflac’s financial position is probably the best insurance for investor… Read More